Medtronic announces fda approval of minimally invasive device to treat hypertension

The symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure approval is the culmination of ten years of clinical research and development of the medtronic renal denervation technology dublin, nov. 17, 2023 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that the united states food and drug administration (fda) has approved the symplicity spyral™ renal denervation (rdn) system, also known as the symplicity™ blood pressure procedure, for the treatment of hypertension. with this approval, medtronic will immediately begin commercialization.
MDT Ratings Summary
MDT Quant Ranking